Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Wellstein

Showing results (31-40 of 104) with videos related to

Pageof 11
Sort By:
Histology and Histopathology|December 4, 2004
Gene expression analysis in sections and tissue microarrays of archival tissues by mRNA in situ hybridizationR T Henke, A Maitra, S Paik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinomaE D Liaudet-Coopman, G J Berchem, A Wellstein
European Journal of Clinical Pharmacology|January 1, 1986
Transdermal delivery of bupranolol: pharmacodynamics and beta-adrenoceptor occupancyA Wellstein, H Küppers, H F Pitschner, et al.
Experimental Cell Research|August 1, 1997
Differential regulation of extracellular signal-regulated kinase 1 and 2 activity during 12-O-tetradecanoylphorbol 13-acetate-induced differentiation of HL-60 cellsR L Meighan-Mantha, A Wellstein, A T Riegel
The Journal of Biological Chemistry|December 31, 1997
HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targetingH Juhl, S G Downing, A Wellstein, et al.
Biochemical and Biophysical Research Communications|September 16, 1992
Structure of the human heparin-binding growth factor gene pleiotrophinS Lai, F Czubayko, A T Riegel, et al.
Biochemical Society Symposium|March 26, 1998
Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophinA Kurtz, E Spitzer, W Zschiesche, et al.
Arzneimittel-Forschung|January 1, 1985
Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockersA Wellstein, D Palm, G G Belz, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 1996
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophinF Czubayko, A M Schulte, G J Berchem, et al.
Methods and Findings in Experimental and Clinical Pharmacology|December 1, 1985
In vitro receptor occupancy allows to establish equieffective doses of beta-blockers with different pharmacodynamic profiles in man. Investigations with propranolol and bufuralolA Wellstein, D Palm, J H Matthews, et al.
Pageof 11

Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Histology and Histopathology|December 4, 2004
Gene expression analysis in sections and tissue microarrays of archival tissues by mRNA in situ hybridizationR T Henke, A Maitra, S Paik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinomaE D Liaudet-Coopman, G J Berchem, A Wellstein
European Journal of Clinical Pharmacology|January 1, 1986
Transdermal delivery of bupranolol: pharmacodynamics and beta-adrenoceptor occupancyA Wellstein, H Küppers, H F Pitschner, et al.
Experimental Cell Research|August 1, 1997
Differential regulation of extracellular signal-regulated kinase 1 and 2 activity during 12-O-tetradecanoylphorbol 13-acetate-induced differentiation of HL-60 cellsR L Meighan-Mantha, A Wellstein, A T Riegel
The Journal of Biological Chemistry|December 31, 1997
HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targetingH Juhl, S G Downing, A Wellstein, et al.
Biochemical and Biophysical Research Communications|September 16, 1992
Structure of the human heparin-binding growth factor gene pleiotrophinS Lai, F Czubayko, A T Riegel, et al.
Biochemical Society Symposium|March 26, 1998
Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophinA Kurtz, E Spitzer, W Zschiesche, et al.
Arzneimittel-Forschung|January 1, 1985
Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockersA Wellstein, D Palm, G G Belz, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 1996
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophinF Czubayko, A M Schulte, G J Berchem, et al.
Methods and Findings in Experimental and Clinical Pharmacology|December 1, 1985
In vitro receptor occupancy allows to establish equieffective doses of beta-blockers with different pharmacodynamic profiles in man. Investigations with propranolol and bufuralolA Wellstein, D Palm, J H Matthews, et al.
Pageof 11